General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview


  • Lautropia mirabilis is a Gram-negative, non-spore-forming, facultatively anaerobic, motile, coccus bacterium. It has been detected in at least 7 gut microbiome compilation studies or metastudies. The DNA G+C content is 64.6-65.4%. Lautropia mirabilis is probably a common, although minor, coloniser of the gut. (GernerSmidt1994; GernerSmidt2005Bergey)



  • This organism has been recovered from human faeces, and human mouth (including sputum, abscess, gingiva - CCUG). The risk classification (www.baua.de) for this organism is 1, i.e., low risk of infection and spread. Pathogenicity status unknown, or very unlikely to be pathogenic. A possible gut commensal.

  • GENERAL CHARACTERISTICS (GernerSmidt1994); (GernerSmidt2005Bergey);
    Character Response
  • Substrates hydrolysed or digested:
  • aesculin; urea;
  • 🧂
  • Salt tolerance:
  • doesn't tolerate 2.5% salt;
  • 🌡
  • Temperature tolerance:
  • grows at 30℃; grows at 45℃;
  • H+
  • Acid from carbohydrates usually produced:
  • fructose; glucose; maltose; sucrose; mannitol;
  • ±
  • Strain-dependent acid from carbs:
  • galactose;
  • Substrates assimilated or utilised:
  • fructose; glucose; mannitol; sucrose;
  • Active enzymes:
  • catalase; esterase C4; γ-Glu transferase; α-glucosidase; β-glucosidase; Leu arylamidase; oxidase; urease; xylosidase;

  • SPECIAL FEATURES (GernerSmidt1994); (GernerSmidt2005Bergey);
    Character Response
  • Metabolites not produced:
  • H₂S; indole;
  • VP test:
  • not active
  • ONPG test:
  • not active
  • Haemolysis:
  • absent
  • Nitrate:
  • reduced
  • Nitrite:
  • reduced
  • Pigments:
  • not produced

  • RESPONSE TO ANTIBIOTICS (GernerSmidt1994); (GernerSmidt2005Bergey);
    Class Active Resistant
  • Penicillins:
  • ampicillin; penicillin G; piperacillin;
  • Cephalosporins:
  • cefuroxime;
  • Macrolides:
  • erythromycin;
  • Aminoglycosides:
  • gentamicin;

  • NOTES

    Able to ferment glucose.

  • Bik, E. M., Eckburg, P. B., Gill, S. R., Nelson, K. E., Purdom, E. A., Francois, F., Perez-Perez, G., Blaser, M. J., & Relman, D. A. (2006). Molecular analysis of the bacterial microbiota in the human stomach. Proceedings of the National Academy of Sciences of the United States of America, 103(3), 732–737.


  • Details


    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Proteobacteria Class:  Betaproteobacteria Order:  Burkholderiales Family:  Burkholderiaceae Genus:  Lautropia Gram stain:  neg O2 Relation.:  facultatively anaerobic Spore:  No spore Motility:  Swimming Morphology:  Coccus Pigment:  neg
    Health:  Unknown
    Source:  human faeces, and human mouth (including sputum, abscess, gingiva - CCUG)
    DNA G+C(%):  64.6-65.4
    Lower T(℃):  30(+)
    High T(℃):  45(+)
    NaCl 3-5%:  2.5(neg)
    Aesculin:  d(+) Urea:  + Gelatin:  neg Starch:  neg Hippurate:  neg Tween:  80(neg)

    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Arabinose:  neg L-Arabinose:  neg Fructose:  + Galactose:  d(neg) Glucose:  + Rhamnose:  neg Ribose:  neg D-Tagatose:  neg Xylose:  neg Lactose:  neg Maltose:  + Melezitose:  neg Sucrose:  + Trehalose:  neg Dextrin:  neg Glycogen:  neg Inulin:  neg Starch:  neg Adonitol:  neg D-Arabitol:  neg Dulcitol:  neg Inositol:  neg Mannitol:  + Sorbitol:  neg Salicin:  neg

    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    Fructose:  + Glucose:  + Sucrose:  + Mannitol:  + Hippurate:  neg

    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Oxidase:  + Catalase:  + Urease:  + Ac-β-glcamnd:  neg α-Fucosidase:  neg α-Galactosidase:  neg β-Galactosidase:  neg α-Glucosidase:  + β-Glucosidase:  + β-Glucuronidase:  neg α-Mannosidase:  neg β-Mannosidase:  neg Xylosidase:  d(+) ArgDH:  neg ArgDC:  neg γ-Glu transf.:  + GluDC:  neg LysDC:  neg OrnDC:  neg Phe deaminase:  neg AlaPheProAA:  neg LeuAA:  + PyrrolidAA:  neg AcidP:  vr Esterase(C4):  + EstLip(C8):  vr Lipase:  vr Lipase(C14):  neg

    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    H2S:  neg Indole:  neg Pigment:  neg

    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    ampicillin:  Sens
    penicillin_G:  Sens
    piperacillin:  Sens
    cefuroxime:  Sens
    gentamicin:  Sens
    erythromycin:  Sens
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)

    References


    SPECIFIC REFERENCES FOR LAUTROPIA MIRABILIS
  • GernerSmidt1994 - Lautropia mirabilis gen. nov., sp. nov., a Gram-negative motile coccus with unusual morphology isolated from the human mouth.
  • GernerSmidt2005Bergey - Bergey's manual of systematic bacteriology. Vol. 2, The Alpha-, Beta-, Delta-, and Epsilonproteobacteria Part C. Family Burkholderiaceae, Genus III. Lautropia
  • Wang2019a - Alterations in Gut Glutamate Metabolism Associated with Changes in Gut Microbiota Composition in Children with Autism Spectrum Disorder
  • ...............................
  • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR LAUTROPIA MIRABILIS
  • Bik2006 - Molecular analysis of the bacterial microbiota in the human stomach.
  • Byrd2020 - Stability and dynamics of the human gut microbiome and its association with systemic immune traits.
  • De2020 - Metagenomic analysis of gut microbiome and resistome of diarrheal fecal samples from Kolkata, India, reveals the core and variable microbiota including signatures of microbial dark matter.
  • New2022 - Collective effects of human genomic variation on microbiome function.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Zeller2014 - Potential of fecal microbiota for early-stage detection of colorectal cancer
  • ...............................